Cell metabolismJul 7, 2026

GLP-1 and Fatty Liver Disease: Effects Beyond Weight Loss

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 8, 2026

Abstract

Glucagon-like peptide 1 (GLP-1) receptors on intrahepatic sinusoidal endothelial cells are key mediators of semaglutide's hepatoprotective effects.

Semaglutide may exert protective effects on the liver independent of weight loss.
The study highlights the role of GLP-1 receptors in liver health.
Understanding these mechanisms could lead to better therapeutic approaches for metabolic dysfunction-associated steatohepatitis.

Simplified

Metabolic dysfunction-associated steatohepatitis (MASH) remains a major unmet clinical challenge. A new study by Gonzalez-Rellan et al.¹ shows that glucagon-like peptide 1 (GLP-1) receptors on intrahepatic sinusoidal endothelial cells are key mediators of semaglutide's weight loss-independent hepatoprotective effects, reframing our understanding of how GLP-1-based therapies act within the diseased liver.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of interests M.T.L., N.K., and F.K.K. are employees and shareholders at Novo Nordisk A/S.

PubMed

Featured in

GLP-1 Therapies

GLP-1 TherapiesIssue #45

Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients

yesterday7 studies

Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study

1 week ago7 studies

Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients

2 weeks ago7 studies

Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group

3 weeks ago8 studies

New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients

4 weeks ago7 studies

GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery

5 weeks ago7 studies

Semaglutide linked to reduced cigarette craving in 24 smokers

6 weeks ago7 studies

Two-thirds of patients kept weight off after stopping GLP-1 drugs

7 weeks ago7 studies

Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months

9 weeks ago7 studies

Semaglutide linked to 2.5x higher risk of sudden vision loss

10 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief